Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/10539Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kostapanos, M. S. | en |
| dc.contributor.author | Derdemezis, C. S. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Milionis, H. J. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T16:57:07Z | - |
| dc.date.available | 2015-11-24T16:57:07Z | - |
| dc.identifier.issn | 0014-2999 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/10539 | - |
| dc.rights | Default Licence | - |
| dc.subject | adipokine | en |
| dc.subject | hyperlipidemia | en |
| dc.subject | rosuvastatin | en |
| dc.subject | visfatin | en |
| dc.subject | colony-enhancing factor | en |
| dc.subject | type-2 diabetes-mellitus | en |
| dc.subject | atorvastatin | en |
| dc.subject | protein | en |
| dc.title | Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | DOI 10.1016/j.ejphar.2007.09.019 | - |
| heal.identifier.secondary | <Go to ISI>://000252870600020 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0014299907010461/1-s2.0-S0014299907010461-main.pdf?_tid=152939bcf612750452cd35fc1ce2ae3c&acdnat=1333111400_4fd422d14f9466d610b7258ecfa4ecd2 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Visfatin is a novel adipokine involved in the process of atherosclerosis. We assessed the effect of rosuvastatin on plasma visfatin levels in patients with primary hyperlipidemia. Eighty hyperlipidemic patients without evidence of cardiovascular disease were randomized to receive either rosuvastatin 10 mg/day or therapeutic lifestyle changes intervention. Plasma visfatin levels were determined at baseline and after 12-weeks post-randomization. Rosuvastatin induced a significant decrease in plasma visfatin levels (17.1 +/- 2.1 versus 15.5 +/- 2.0 ng/ml, P = 0.03). This effect correlated with baseline visfatin levels (r=0.51, P<0.01) and was independent of any lipid-lowering actions of rosuvastatin. (C) 2007 Elsevier B.V. All rights reserved. | en |
| heal.journalName | European Journal of Pharmacology | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Kostapanos-2008-Effect of rosuvastat.pdf | 123.43 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
